Background/Objective: Since 2004, seasonal influenza vaccination has been technically recommended for poultry workers as a public health measure to reduce the risk of co-infection with human and avian influenza viruses and the potential emergence of reassortant strains. The Latin America and the Caribbean (LAC) region has co-circulation of seasonal and avian influenza, with outbreaks in different animal species, including humans. Also, LAC is a major poultry-producing region, with large workforces exposed to domestic poultry, increasing opportunities for virus transmission at the human–animal interface. This review aimed to describe the current state of seasonal influenza vaccination policies across 33 LAC countries and to identify which countries explicitly mention poultry workers. Methods: We conducted a literature review with structured and iterative search strategies from the electronic Joint Reporting Form on Immunization (eJRF) and the national health authorities’ websites of the 33 countries. Results: As of July 2026, eight countries explicitly included poultry workers among the target groups for seasonal influenza vaccination: Chile, Costa Rica, Cuba, Ecuador, Guatemala, Honduras, Peru and Uruguay. In contrast, 14 countries did not mention poultry workers in their most recent vaccination policies available online. For 11 countries, no publicly available data was identified. Conclusions: Substantial gaps exist in the adoption and reporting of seasonal influenza vaccination policies for poultry workers across the LAC region. Most of the region’s major poultry-producing countries do not specifically target this group, nor do most of the countries where outbreaks of avian influenza were recorded. This represents a missed opportunity to strengthen prevention efforts at the human–animal interface.
Background: Influenza imposes a substantial burden on Argentina, particularly among adults aged 50–64 with comorbidities and those aged ≥65. The adjuvanted trivalent influenza vaccine (aTIV) has shown superior effectiveness compared with non-adjuvanted vaccines; however, its cost-effectiveness and budget impact in the 50–64 high-risk population have not been assessed nationally. This study evaluates the cost-effectiveness and budget impact of introducing aTIV for high-risk adults aged 50–64, alongside its use in adults aged ≥65, compared with standard-dose trivalent influenza vaccine (SD-TIV) from the Argentine health care system perspective. Methods: A decision-analytic static model was used to compare aTIV with SD-TIV over a single influenza season. In addition, a 5-year budget impact analysis (BIA) was conducted under scenarios of progressive uptake. Model inputs were derived from international literature, local data, and expert opinion. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared with SD-TIV, aTIV yielded a lifetime gain of 1489 quality-adjusted life-years (QALYs) at an incremental cost of USD 8.34 million, resulting in an incremental cost-effectiveness ratio (ICER) of USD 5599 per QALY gained—well below Argentina’s cost-effectiveness threshold (USD 11,059/QALY). Higher vaccine acquisition costs were largely offset by reductions in outpatient visits and hospitalizations. The BIA showed a modest average annual per-member-per-month increase of USD 0.0025, remaining below the estimated budget impact threshold (USD 0.0065). Conclusions: Implementing aTIV in adults aged ≥50 with risk factors would be cost-effective and affordable in Argentina. These findings support the consolidation and potential expansion of current vaccination strategies to reduce influenza burden.
La adecuada aptitud inmunitaria permite el establecimiento de hábitos de vida que pueden mejorar nuestra capacidad inmunitaria: buenas relaciones sociales, limitar el consumo de alcohol, aumentar la actividad física y controlar los niveles de estrés. Revisión narrativa de las principales bases de datos científicos entre 1996- 2025 con el objetivo de relacionar los cambios en la aptitud inmunitaria del adulto mayor que envejece, el tabaco, las enfermedades respiratorias crónicas y la inmunoinflamación crónica que provocan; y el impacto beneficioso terapéutico que ofrece la rehabiltación respiratoria en mejorar la respuesta inmune. La inmunosenescencia es el deterioro gradual del sistema inmunitario causado por la edad. Se asocia con capacidad reducida para responder a infecciones y desarrollar memoria inmunitaria a largo plazo. Es clave en el desarrollo de enfermedades respiratorias muy frecuentes en personas mayores, como el asma, la EPOC, enfermedad intersticial difusa e infecciones respiratorias en los ancianos. La rehabilitación respiratoria (RR) para pacientes con enfermedades respiratorias crónicas mejora la capacidad para el ejercicio físico. Asimismo, comprende programas de cesación tabáquica, alimentación saludable, educación, tratamiento farmacológico, apoyo en salud mental y vacunación conforme a los calendarios nacionales vigentes, gratuitos y dirigidos a poblaciones de riesgo, como personas con enfermedades respiratorias crónicas, adultos mayores de 50 años y tabaquistas. En conjunto, estas intervenciones pueden contribuir a ralentizar la inmunosenescencia. La RR comparte muchos de los conceptos y componentes relacionados con la mejoría de la aptitud inmunitaria y probablemente sean las razones por las que los pacientes que la cumplen se reagudizan menos.